VIVUS Inc

VIVUS — Proxy Contest (June 2013)

27 slides from VIVUS's proxy contest presentation, Jun 18, 2013

  1. Slide 1: Innovative Therapies Novel Products

    INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT This presentation contains “forward looking” statements that involve risks and uncertainties. These statements typically may be identified by the use of forward looking words or phrases such as “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “shou

  3. Slide 3: Investment Highlights

    INVESTMENT HIGHLIGHTS Biopharma company with two FDA approved products in markets with high potential Qsymia, the first FDA approved once-daily oral medication for chronic obesity that has demonstrated average weight loss of >10% based on placebo-adjusted data* Obesity is the most prevalent medical

  4. Slide 4: Two approved products in high potential markets

    INNOVATIVE THERAPIES; NOVEL PRODUCTS Two approved products in high potential markets: Qsymia® for chronic weight management STENDRA™ for erectile dysfunction ©2013 VIVUS Inc. All rights reserved | www.vivus.com 3

  5. Slide 5: Qsymia Prescribing Information

    QSYMIA PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 4

  6. Slide 6: Qsymia Magnitude of Effect

    QSYMIA MAGNITUDE OF EFFECT PIVOTAL 1-YEAR STUDIES: WEIGHT LOSS OVER TIME (OBSERVED/ITT DATA) ©2013 VIVUS Inc. All rights reserved | www.vivus.com 5 Study 1 (EQUIP1) Study 2 (CONQUER2) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or

  7. Slide 7: Qsymia Consistency of Effect

    QSYMIA CONSISTENCY OF EFFECT ©2013 VIVUS Inc. All rights reserved | www.vivus.com 6 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 30

  8. Slide 8: Beneficial Effects of Weight Loss with Qsymia

    BENEFICIAL EFFECTS OF WEIGHT LOSS WITH QSYMIA ©2013 VIVUS Inc. All rights reserved | www.vivus.com 7 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted

  9. Slide 9: VIVUS Has Recently Achieved Important Milestones for Qsymia

    VIVUS HAS RECENTLY ACHIEVED IMPORTANT MILESTONES FOR QSYMIA Increases in prescriptions, prescribers & patients Publication of pharmacoeconomic data (Mar-2013) Medco coverage of Qsymia (Apr-2013) Approval of REMS modification to allow access via certified retail pharmacies (Apr-2013) Veterans Adminis

  10. Slide 10: Steady Growth in Qsymia Prescriptions, Prescribers & Patients

    Prescriptions Prescribers Patients Launch thru Mar-2013 89,548 14,914 39,529 Source: VIVUS, Inc. Data on file – 31-Mar-2013 Q-o-Q Growth % 97% STEADY GROWTH IN QSYMIA PRESCRIPTIONS, PRESCRIBERS & PATIENTS 9

  11. Slide 11: REMS Modification Allows Qsymia Distribution via Retail Channel

    REMS MODIFICATION (APR-2013) ALLOWS QSYMIA DISTRIBUTION VIA RETAIL CHANNEL Removes a significant barrier to Qsymia commercialization Simplifies prescribing and dispensing Availability in thousands of certified retail pharmacies expected by mid-Jul-2013 ©2013 VIVUS Inc. All rights reserved | www.vivu

  12. Slide 12: Retail Implementation Plan on Track for Mid-July 2013

    RETAIL IMPLEMENTATION PLAN ON TRACK FOR MID-JULY 2013 Execute wholesaler distribution agreements Build distribution network Build and validate REMS-compliant databases Enroll, train and certify pharmacies (chain/independent) Ship to distribution centers Stock thousands of certified pharmacies ©2013

  13. Slide 13: Qsymia Insurance Plan Coverage Is Growing

    QSYMIA INSURANCE PLAN COVERAGE IS GROWING ~36% of U.S. Commercial Lives have access to Qsymia at Tier 3 or better with a co-pay of $75.00 or less for most patients* Early success with both national and regional PBMs and health plans YE 2013 Goal: 50% *Source: HealthLeaders (Jul-2012); Data on File,

  14. Slide 14: Qsymia Covered by VA; Reduces Out-of-Pocket Costs for Veterans

    QSYMIA COVERED BY VA; REDUCES OUT-OF-POCKET COSTS FOR VETERANS Qsymia now available for 3.3 million Veterans Administration (VA) patients for $9.00 copay Prevalence of obesity: ~40% Criteria for Use (CFU) consistent with Qsymia label 1st U.S. government entity to grant access to Qsymia Conservative

  15. Slide 15: AACE Diabetes Management Algorithm 2013 Includes Anti-Obesity Medications

    AACE DIABETES MANAGEMENT ALGORITHM 2013 INCLUDES ANTI-OBESITY MEDICATIONS Obesity categorized as a medical condition warranting treatment Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension Inclusion of weight loss medicati

  16. Slide 16: AACE Treatment Guidelines Include Anti-Obesity Medications

    AACE TREATMENT GUIDELINES INCLUDE ANTI-OBESITY MEDICATIONS Reprinted with permission from American Association of Clinical Endocrinologists. Garber AJ, Abrahamson, MJ, Brazilay JI, et al. AACE Comprehensive Diabetes Management Algorithm. Endocr Pract. 2013;19:327-336 16

  17. Slide 17: Publication of Pharmacoeconomic Data Helps Reimbursement

    PUBLICATION OF PHARMACOECONOMIC DATA HELPS REIMBURSEMENT 10%-15% weight loss = gross per capita savings of ~$6,000-$13,000 over 10 years With ~11.2 million Medicare patients who are obese or overweight with at least one weight-related comorbidity, lifetime savings could total billions of dollars Stu

  18. Slide 18: Building the Qsymia Franchise

    Educate Physicians; Engineer Patient Starts Broaden Reimbursement Expand to Retail Pharmacies DTC & Expand PCP Reach BUILDING THE QSYMIA FRANCHISE ©2013 VIVUS Inc. All rights reserved | www.vivus.com 18 Launch Time Rx Growth

  19. Slide 19: VIVUS Continues to Execute on Its Plan for Qsymia

    VIVUS CONTINUES TO EXECUTE ON ITS PLAN FOR QSYMIA 2013 Remaining Qsymia Goals Continue to build brand awareness among healthcare providers and patients Improve access through certified retail pharmacies Continue to expand insurance coverage Initiate DTC campaign to activate consumers Continue discus

  20. Slide 20: Qsymia Has a Strong Patent Position

    QSYMIA HAS A STRONG PATENT POSITION VIVUS has issued patents that protect Qsymia into mid-2020 Four issued US patents listed in the Orange Book European patent validated in 19 countries Patents in Canada and Australia If approved, market exclusivity in the EU may be available for 10 years, outside o

  21. Slide 21: STENDRA: Partnering for Value

    STENDRA: PARTNERING FOR VALUE ©2013 VIVUS Inc. All rights reserved | www.vivus.com

  22. Slide 22: STENDRA Prescribing Information

    STENDRA™ PRESCRIBING INFORMATION ©2013 VIVUS Inc. All rights reserved | www.vivus.com 22

  23. Slide 23: STENDRA

    STENDRA™ Highly selective PDE5i with rapid onset Positive CHMP recommendation (Apr. 26, 2013) Opportunity to commercialize in the US and EU EC decision expected Jun-2013 Manufacturing technology transfer underway Partnering discussions in progress ©2013 VIVUS Inc. All rights reserved | www.vivus.com

  24. Slide 24: VIVUS Is Well-Capitalized to Execute on Its Strategy

    VIVUS IS WELL-CAPITALIZED TO EXECUTE ON ITS STRATEGY $360MM of new financing secured in the last three months to execute commercialization of Qsymia $250MM Convertible Senior Unsecured Notes (May 21, 2013) Capped call brings effective conversion price to $20.00 $110MM synthetic capped royalty financ

  25. Slide 25: VIVUS Investment Highlights

    VIVUS INVESTMENT HIGHLIGHTS Two FDA-approved products Making significant progress in building the obesity category and Qsymia brand Educating physicians Expanding reimbursement Improving access (REMS modification) Growing Qsymia prescriptions Strong Balance Sheet ©2013 VIVUS Inc. All rights reserved

  26. Slide 26: Important Additional Information

    IMPORTANT ADDITIONAL INFORMATION On June 3, 2013, VIVUS filed a definitive proxy statement and GOLD proxy card with the SEC in connection with the solicitation of proxies for its 2013 Annual Meeting of Stockholders. Stockholders are strongly advised to read VIVUS’s 2013 proxy statement because it co

  27. Slide 27: Innovative Therapies Novel Products

    INNOVATIVE THERAPIES NOVEL PRODUCTS ©2013 VIVUS Inc. All rights reserved | www.vivus.com

Vivus — Proxy Contest (June 2013) on 6ix